186 related articles for article (PubMed ID: 11253161)
1. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk.
Castaño G; Más R; Fernández JC; Illnait J; Fernández L; Alvarez E
J Gerontol A Biol Sci Med Sci; 2001 Mar; 56(3):M186-92. PubMed ID: 11253161
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women.
Mirkin A; Mas R; Martinto M; Boccanera R; Robertis A; Poudes R; Fuster A; Lastreto E; Yañez M; Irico G; McCook B; Farré A
Int J Clin Pharmacol Res; 2001; 21(1):31-41. PubMed ID: 11708573
[TBL] [Abstract][Full Text] [Related]
3. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
Castaño G; Mas R; Fernández L; Illnait J; Mesa M; Alvarez E; Lezcay M
Drugs Aging; 2003; 20(2):153-63. PubMed ID: 12534315
[TBL] [Abstract][Full Text] [Related]
5. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E
Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574
[TBL] [Abstract][Full Text] [Related]
6. Concomitant use of policosanol and beta-blockers in older patients.
Castaño G; Mas R; Gámez R; Fernández J; Illnait J; Fernández L; Mendoza S; Mesa M; Gutiérrez JA; López E
Int J Clin Pharmacol Res; 2004; 24(2-3):65-77. PubMed ID: 15689053
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.
Castaño G; Más R; Fernández L; Illnait J; Mendoza S; Gámez R; Fernández J; Mesa M
Drugs Exp Clin Res; 2005; 31 Suppl():31-44. PubMed ID: 16444910
[TBL] [Abstract][Full Text] [Related]
8. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.
Castaño G; Fernández L; Mas R; Illnait J; Gámez R; Mendoza S; Mesa M; Fernández J
Drugs R D; 2005; 6(4):207-19. PubMed ID: 16050054
[TBL] [Abstract][Full Text] [Related]
9. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
[TBL] [Abstract][Full Text] [Related]
10. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors.
Más R; Castaño G; Illnait J; Fernández L; Fernández J; Alemán C; Pontigas V; Lescay M
Clin Pharmacol Ther; 1999 Apr; 65(4):439-47. PubMed ID: 10223782
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hypercholesterolemia in NIDDM with policosanol.
Torres O; Agramonte AJ; Illnait J; Más Ferreiro R; Fernández L; Fernández JC
Diabetes Care; 1995 Mar; 18(3):393-7. PubMed ID: 7555484
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.
Crespo N; Illnait J; Más R; Fernández L; Fernández J; Castaño G
Int J Clin Pharmacol Res; 1999; 19(4):117-27. PubMed ID: 10939029
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia.
Castaño G; Fernández L; Mas R; Illnait J; Fernández J; Mesa M; Alvarez E; Lezcay M
Int J Clin Pharmacol Res; 2002; 22(2):55-66. PubMed ID: 12503776
[TBL] [Abstract][Full Text] [Related]
14. Effects of policosanol on postmenopausal women with type II hypercholesterolemia.
Castaño G; Más R; Fernández L; Fernández JC; Illnait J; López LE; Alvarez E
Gynecol Endocrinol; 2000 Jun; 14(3):187-95. PubMed ID: 10923280
[TBL] [Abstract][Full Text] [Related]
15. Policosanol: a new treatment for cardiovascular disease?
Janikula M
Altern Med Rev; 2002 Jun; 7(3):203-17. PubMed ID: 12126462
[TBL] [Abstract][Full Text] [Related]
16. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial.
Dulin MF; Hatcher LF; Sasser HC; Barringer TA
Am J Clin Nutr; 2006 Dec; 84(6):1543-8. PubMed ID: 17158441
[TBL] [Abstract][Full Text] [Related]
17. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
[TBL] [Abstract][Full Text] [Related]
18. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects.
Greyling A; De Witt C; Oosthuizen W; Jerling JC
Br J Nutr; 2006 May; 95(5):968-75. PubMed ID: 16611388
[TBL] [Abstract][Full Text] [Related]
19. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.
Cubeddu LX; Cubeddu RJ; Heimowitz T; Restrepo B; Lamas GA; Weinberg GB
Am Heart J; 2006 Nov; 152(5):982.e1-5. PubMed ID: 17070175
[TBL] [Abstract][Full Text] [Related]
20. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
Pons P; Rodríguez M; Robaina C; Illnait J; Más R; Fernández L; Fernández JC
Int J Clin Pharmacol Res; 1994; 14(1):27-33. PubMed ID: 7927958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
